Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Relación entre los niveles de tacrolimus y/o dosis de micofenolato y la modulación de los genes de rechazo en biopsias de seguimiento del aloinjerto renal

IP: Daniel Serón Micas
Collaborators: Joana Sellarés Roig, Concepció Jacobs Cachá, Manel Perelló Carrascosa
Funding agency: Instituto de Salud Carlos III
Funding: 81070
Reference: PI18/01704
Duration: 01/01/2019 - 31/12/2021

Apolipoproteína AIb como biomarcador y diana terapéutica de la glomeruloesclerosis segmentaria y focal idiopática (GESF)

IP: Joan López Hellin
Collaborators: José Antonio Arranz Amo, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Instituto de Salud Carlos III
Funding: 88935
Reference: PI14/00275
Duration: 01/01/2015 - 30/06/2018

Promoting regeneration versus tubulointerstitial fibrosis in progressive renal disease: Novel molecular pathways

IP: Anna Meseguer Navarro
Collaborators: Joan López Hellin, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Sociedad Española de Nefrología (S.E.N.)
Funding: 18000
Reference: SENEFRO-2012-01
Duration: 06/10/2012 - 05/10/2014

Red de investigación Renal

IP: Daniel Serón Micas
Collaborators: Joan López Hellin, Anna Meseguer Navarro, Francesc Moreso Mateos, Enric Trilla Herrera, Natalia Ramos Terrades, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá, Manel Perelló Carrascosa
Funding agency: Instituto de Salud Carlos III
Funding: 92250
Reference: RD12/0021/0013
Duration: 01/01/2013 - 31/12/2016

Related news

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Related professionals

Marc Ribó Jacobi

Marc Ribó Jacobi

Main researcher
Stroke research
Read more
Raquel Maria Lastra Borras

Raquel Maria Lastra Borras

Research technician
Headache and Neurological Pain
Read more
Lara Grau Lopez

Lara Grau Lopez

Psychiatry, Mental Health and Addictions
Read more
Iris Garcia Martínez

Iris Garcia Martínez

Postdoctoral researcher
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.